<DOC>
	<DOCNO>NCT02231281</DOCNO>
	<brief_summary>The purpose study assess ability early initiation cART cART combination autologous HIV-1 specific cytotoxic T lymphocyte ( CTL ) infusion achieve post-treatment control among treatment-naïve acute HIV-infected adult .</brief_summary>
	<brief_title>Early cART cART Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte ( CTL ) Infusion The Treatment Acute HIV-1 Infected Adults</brief_title>
	<detailed_description>Although combined antiretroviral therapy ( cART ) suppress HIV-1 replication low level blood , eliminate latent viral reservoir , need lifelong adherence expensive regimens potential side effect . Increasing evidence indicate early antiretroviral therapy recently HIV-infected patient result slow progression HIV disease represent unique opportunity interfere either quantity quality persistent reservoir replication-competent virus . However , time course interruption cART unclear . This study compare virological immunological outcome HIV latency recently infect adult receive cART cART combination autologous HIV-1 CTL infusion different period . The study last 120 week . Participants randomly assign either cART cART plus autologous HIV-1 CTL infusion arm one three cohort . The three cohort differ period cART give . Cohort 1 , Cohort 2 Cohort 3 receive cART ( Zidovudine ( AZT ) /Tenofovir disoproxil fumarate ( TDF ) +Lamivudine ( 3TC） + Lopinavir / Ritonavir （LPV/r ) ） 48 , 72 96 week , respectively . After 48 , 72 96 week , cART interrupt respectively . Study visit occur study entry , Week 4 12 , every 12 week thereafter treatment interruption , every 4 week 12 week later , every 12 week Week 120 . At study visit , physical exam , blood collection , completion adherence questionnaire occur . Clinical , virological , immunological evaluation HIV latency examination perform study visit .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>1 . Diagnosis acute HIV infection ( meet one follow criterion ) 1 . Negative antiHIV test formerly , antiHIV serological conversion within 6 month 2 . Detection plasma HIV RNA RTPCR absence HIV antibody 3 . Lowlevel antiHIV BED HIV1 capture enzyme immuno assay ( BEDCEIA ) , optical density ( OD ) &lt; 0.6 , B subtype ) 4 . Uncertain antiHIV test , increase antiHIV level repeat test within two week 5 . A patient report recent risk behavior association symptom sign acute retroviral syndrome , well positive HIV antigen detection le 4 band Western blot assay 2 . Ability , willingness give inform consent 3 . Able , willing adhere therapy adherent ART 4 . Able , willing comply time requirement study visit evaluation 1 . Chronic HIV 1 infection 2 . Any evidence active AIDSdefining opportunistic infection 3 . Screening detects follow result : HGB &lt; 90g/L、WBC &lt; 2 x 10E9/L、PLT &lt; 75 x 10E9/L、hemodiastase &gt; 2 x ULN、Scr &gt; 1.5 x ULN、ALT/AST/ALP &gt; 3 xULN、TbiL &gt; 2 xULN、CK &gt; 2 xULN、CCr &lt; 60ml/min 4 . A personal history clinically significant cardiac disease , symptomatic asymptomatic arrhythmia , syncopal episode , additional risk factor torsades de point 5 . History chronic kidney disease 6 . History malignancy transplantation , include skin cancer Kaposi sarcoma 7 . History Severe peptic ulcer 8 . History alcoholism drug abuse 9 . Receipt immunomodulating agent , immunization systemic chemotherapeutic agent within 28 day prior screen 10 . Women pregnant breastfeeding , positive pregnancy test screen Women Child Bearing Potential ( WOCBP ) unwilling unable use acceptable method contraception avoid pregnancy entire study period 11 . Have contraindication cART 12 . Other condition fit participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Immunologic Deficiency Syndromes</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Lentivirus Infections</keyword>
	<keyword>Retroviridae Infections</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Sexually Transmitted Diseases , Viral</keyword>
	<keyword>Slow Virus Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>Early therapy</keyword>
</DOC>